secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0001140361-24-035756
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharma H1 2024 net loss $131.7M; KRESLADI review ongoing, cash into 2026
-------------------------------------------------------------------------------

- Net loss of $131.7M ($1.40/sh) for H1 2024 vs $124.0M ($1.55/sh) for H1 2023.
- Cash, equivalents & investments $278.8M; runway expected into 2026.
- FDA requested additional CMC info for KRESLADI (LAD-I); working to support approval.
- Phase 2 pivotal enrollment ongoing for RP-A501 (Danon) and RP-L301 (PKD) initiated.
- EC granted orphan medicinal product designation for RP-A601 (PKP2-ACM); Phase 1 enrolling.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036124035756/0001140361-24-035756-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036124035756/ef20033571_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-035756

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer